Why Recursion Pharamaceuticals Topped the Market Today

The company appears to be on track to develop a commercialized product through its drug discovery system.Recursion Pharmaceuticals (RXRX +2.33%) was in the headlines on Monday, and for the right reason. One of the biotech company's investigational drugs did well in a clinical trial, and investors rewarded the company by trading its stock more than 2% higher on the news. A very encouraging trialBefore market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The d ...